APA (7th ed.) Citation

Rabbani, S. A., Saini, M., El-Tanani, M., Kumar, R., Matalka, I., El-Tanani, Y., . . . Rizzo, M. (2026). Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies. Pharmaceuticals (14248247), 19(5), 732. https://doi.org/10.3390/ph19050732

Chicago Style (17th ed.) Citation

Rabbani, Syed Arman, Manita Saini, Mohamed El-Tanani, Rakesh Kumar, Ismail Matalka, Yahia El-Tanani, Shrestha Sharma, and Manfredi Rizzo. "Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies." Pharmaceuticals (14248247) 19, no. 5 (2026): 732. https://doi.org/10.3390/ph19050732.

MLA (9th ed.) Citation

Rabbani, Syed Arman, et al. "Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies." Pharmaceuticals (14248247), vol. 19, no. 5, 2026, p. 732, https://doi.org/10.3390/ph19050732.